Waldenström makroglobulinemili hastada rituksimab tedavisi sonrası gelişen gizli hepatit B reaktivasyonu
The anti-CD20 monoclonal antibody rituximab has beenused extensively in the treatment of B-cell lymphoma.Several studies reported hepatitis B virus (HBV) reactivationafter rituximab. The majority of these cases havebeen described in chronic carriers of HBV, whereas reactivationin occult hepatitis B...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Modestum Publishing LTD
2012-12-01
|
| Series: | Journal of Clinical and Experimental Investigations |
| Subjects: | |
| Online Access: | http://www.jceionline.org/upload/sayi/11/JCEI-00492.pdf |